Viking Therapeutics Shares Dip as Pfizer Chooses Rival Acquisition

A Shifting Competitive Landscape

Viking Therapeutics experienced significant selling pressure yesterday as investors reacted to Pfizer’s unexpected acquisition of competitor Metsera. The biotech firm’s shares declined 4.88% to close at $24.97, a notable setback for shareholders who had anticipated Viking itself might become a takeover target.

The pharmaceutical giant’s move to acquire Metsera represents a significant reshuffling of the competitive dynamics within the obesity drug market. This development is particularly impactful for Viking, as Pfizer had long been considered a prime candidate to acquire the company. This speculation intensified after Pfizer discontinued its internal GLP-1 drug development program, leaving Viking without a previously speculated potential buyer.